Skip to content

ANAVEX LIFE SCIENCES CORP.: 10-Q filed 2017-05-10

What ANAVEX LIFE SCIENCES CORP. reported in its quarterly report filed 2017-05-10 (fiscal Q2 2017): 20 published measures, 60 facts as tagged in accession 0001615774-17-002182.

This filing

Form
10-Q (quarterly report)
Filed
2017-05-10
Fiscal period
fiscal Q2 2017
Accession
0001615774-17-002182 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ANAVEX LIFE SCIENCES CORP. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-03-3123,606,588USD
At 2016-09-309,498,681USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-03-3121,486,691USD
At 2016-09-306,308,156USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-1,549,087USD90
2016-10-01 to 2017-03-31-4,695,746USD182
2016-01-01 to 2016-03-31-2,030,801USD91
2015-10-01 to 2016-03-31-5,985,310USD183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-03-31-82,713,899USD
At 2016-09-30-78,018,153USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2017-01-01 to 2017-03-3141,159,707shares90
2016-10-01 to 2017-03-3139,761,612shares182
2016-01-01 to 2016-03-3135,214,793shares91
2015-10-01 to 2016-03-3134,589,957shares183

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2017-01-01 to 2017-03-3141,159,707shares90
2016-10-01 to 2017-03-3139,761,612shares182
2016-01-01 to 2016-03-3135,214,793shares91
2015-10-01 to 2016-03-3134,589,957shares183

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-0.04USD/shares90
2016-10-01 to 2017-03-31-0.12USD/shares182
2016-01-01 to 2016-03-31-0.06USD/shares91
2015-10-01 to 2016-03-31-0.17USD/shares183

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-0.04USD/shares90
2016-10-01 to 2017-03-31-0.12USD/shares182
2016-01-01 to 2016-03-31-0.06USD/shares91
2015-10-01 to 2016-03-31-0.17USD/shares183

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-10-01 to 2017-03-311,858,160USD182
2015-10-01 to 2016-03-311,048,710USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-03-3123,554,192USD
At 2016-09-309,446,285USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-03-312,119,897USD
At 2016-09-303,190,525USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-01-01 to 2017-03-313,608,947USD90
2016-10-01 to 2017-03-316,777,621USD182
2016-01-01 to 2016-03-312,180,168USD91
2015-10-01 to 2016-03-316,712,602USD183

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-01-01 to 2017-03-312,492,933USD90
2016-10-01 to 2017-03-314,535,423USD182
2016-01-01 to 2016-03-311,090,527USD91
2015-10-01 to 2016-03-312,729,856USD183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-03-3141,376,061shares
At 2016-09-3036,168,299shares

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2017-01-01 to 2017-03-31-1,539,492USD90
2016-10-01 to 2017-03-31-4,655,143USD182
2016-01-01 to 2016-03-31-2,030,801USD91
2015-10-01 to 2016-03-31-5,967,695USD183

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-01-01 to 2017-03-311,116,014USD90
2016-10-01 to 2017-03-312,242,198USD182
2016-01-01 to 2016-03-311,089,641USD91
2015-10-01 to 2016-03-313,982,746USD183

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2015-10-01 to 2016-03-31497USD183

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2017-01-01 to 2017-03-312,069,455USD90
2016-10-01 to 2017-03-312,122,478USD182
2016-01-01 to 2016-03-31149,367USD91
2015-10-01 to 2016-03-31744,907USD183

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2017-01-01 to 2017-03-319,595USD90
2016-10-01 to 2017-03-3140,603USD182
2015-10-01 to 2016-03-3117,615USD183

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2016-10-01 to 2017-03-31-18,711USD182
2015-10-01 to 2016-03-311,830USD183

Inspect the source

Entity
ANAVEX LIFE SCIENCES CORP. / CIK 0001314052
Captured
2026-09-20T07:51:32.244Z
SEC response SHA-256
58235b1aa01b2e3fa186f80cce94f8ff6bd171b1d8823aeeecb0ffde54d83b04

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001314052.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))